Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|July 20, 2007
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancerJ-P Delord, J Bennouna, P Artru, et al.
La Revue De Medecine Interne|March 22, 2005
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature]J Desramé, C Duvic, C Bredin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 studyB Chibaudel, C Tournigand, P Artru, et al.
Medical Oncology (Northwood, London, England)|November 6, 2010
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysisM Bouchahda, T Macarulla, G Liedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)D Basile, C Broudin, J F Emile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular studyT André, H Blons, M Mabro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 25, 2024
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world studyR Varnier, C Toullec, S Philonenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatmentA R Thierry, S El Messaoudi, C Mollevi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithmZ Reguiai, J B Bachet, C Bachmeyer, et al.
Pageof 4